Anti-DNA Antibodies: Structure, Regulation and Pathogenicity

Systemic Lupus Erythematosus

Volumn , Issue , 2011, Pages 235-258

  Aranow, Cynthia ^a   Zhou, Dun ^a   Diamond, Betty ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884784715     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374994-9.10014-2     Document Type: Chapter

References (199)

1. Abbas A.K., Lichtman A.H., Pober J.S. Cellular and Molecular Immunology. third ed., Saunders, Philadelphia 1997.
2. Kabat E.A., Wu T.T. Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains. Annals of the New York Academy of Sciences 1971, 190:382-393.
3. Oudin J., Cazenave P.A. Similar idiotypic specificities in immunoglobulin fractions with different antibody functions or even without detectable antibody function. Proceedings of the National Academy of Sciences of the United States of America 1971, 68:2616-2620.
4. Cook G.P., Tomlinson I.M. The human immunoglobulin VH repertoire. Immunology Today 1995, 16:237-242.
5. Fugmann S.D., Lee A.I., Shockett P.E., Villey I.J., Schatz D.G. The RAG proteins and V(D)J recombination: complexes, ends, and transposition. Annual Review of Immunology 2000, 18:495-527.
6. Jeggo P.A., Taccioli G.E., Jackson S.P. Menage a trois: double strand break repair, V(D)J recombination and DNA-PK. Bioessays 1995, 17:949-957.
7. Paull T.T., Gellert M. The 3' to 5' exonuclease activity of Mre 11 facilitates repair of DNA double-strand breaks. Molecular Cell 1998, 1:969-979.
8. van Gent D.C., Hiom K., Paull T.T., Gellert M. Stimulation of V(D)J cleavage by high mobility group proteins. The EMBO Journal 1997, 16:2665-2670.
9. Desiderio S.V., Yancopoulos G.D., Paskind M., Thomas E., Boss M.A., Landau N., et al. Insertion of N regions into heavy-chain genes is correlated with expression of terminal deoxytransferase in B cells. Nature 1984, 311:752-755.
10. Shimuzu A.a.H.T. Immunoglobulin class switching. Cell 1984, 36:801-803.
11. Jaenichen H.R., Pech M., Lindenmaier W., Wildgruber N., Zachau H.G. Composite human VK genes and a model of their evolution. Nucleic Acids Research 1984, 12:5249-5263.
12. Frippiat J.P., Lefranc M.P. Genomic organisation of 34 kb of the human immunoglobulin lambda locus (IGLV): restriction map and sequences of new V lambda III genes. Molecular Immunology 1994, 31:657-670.
13. Heller M., Owens J.D., Mushinski J.F., Rudikoff S. Amino acids at the site of V kappa-J kappa recombination not encoded by germline sequences. The Journal of Experimental Medicine 1987, 166:637-646.
14. Retter M.W., Nemazee D. Receptor editing occurs frequently during normal B cell development. The Journal of Experimental Medicine 1998, 188:1231-1238.
15. Hikida M., Mori M., Takai T., Tomochika K., Hamatani K., Ohmori H. Reexpression of RAG-1 and RAG-2 genes in activated mature mouse B cells. Science New York, NY 1996, 274:2092-2094.
16. Peled J.U., Kuang F.L., Iglesias-Ussel M.D., Roa S., Kalis S.L., Goodman M.F., et al. The biochemistry of somatic hypermutation. Annual Review of Immunology 2008, 26:481-511.
17. Diamond B., Scharff M.D. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proceedings of the National Academy of Sciences of the United States of America 1984, 81:5841-5844.
18. Muramatsu M., Sankaranand V.S., Anant S., Sugai M., Kinoshita K., Davidson N.O., et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. The Journal of Biological Chemistry 1999, 274:18470-18476.
19. Kinoshita K., Honjo T. Linking class-switch recombination with somatic hypermutation. Nature Reviews 2001, 2:493-503.
20. Kocks C., Rajewsky K. Stepwise intraclonal maturation of antibody affinity through somatic hypermutation. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:8206-8210.
21. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
22. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
23. Boule M.W., Broughton C., Mackay F., Akira S., Marshak-Rothstein A., Rifkin I.R. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. The Journal of Experimental Medicine 2004, 199:1631-1640.
24. Tarlinton D. IL-17 drives germinal center B cells?. Nature Immunology 2008, 9:124-126.
25. Ternyck T.a.A.S. Murine natural monoclonal autoantibodies: A study of their polyspecificities and their affinitites. Immunol. Rev 1986, 94.
26. Hayakawa K., Hardy R.R. Development and function of B-1 cells. Current Opinion in Immunology 2000, 12:346-353.
27. Casali P., Notkins A.L. Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes. Annual Review of Immunology 1989, 7:513-535.
28. Suzuki N., Sakane T., Engleman E.G. Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus. The Journal of Clinical Investigation 1990, 85:238-247.
29. Zhang J., Jacobi A.M., Wang T., Berlin R., Volpe B.T., Diamond B. Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. Journal of Autoimmunity 2009, 33:270-274.
30. Murakami M., Yoshioka H., Shirai T., Tsubata T., Honjo T. Prevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells. International Immunology 1995, 7:877-882.
31. Bikah G., Carey J., Ciallella J.R., Tarakhovsky A., Bondada S. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science New York, NY 1996, 274:1906-1909.
32. Schneider P., Takatsuka H., Wilson A., Mackay F., Tardivel A., Lens S., et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. The Journal of Experimental Medicine 2001, 194:1691-1697.
33. Zouali M. The structure of human lupus anti-DNA antibodies. Methods San Diego, Calif 1997, 11:27-35.
34. Wang X., Huang W., Mihara M., Sinha J., Davidson A. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 2002, 168:2046-2053.
35. Wofsy D., Seaman W.E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. The Journal of Experimental Medicine 1985, 161:378-391.
36. Dammers P.M., Visser A., Popa E.R., Nieuwenhuis P., Kroese F.G. Most marginal zone B cells in rat express germline encoded Ig VH genes and are ligand selected. J Immunol 2000, 165:6156-6169.
37. Roark J.H., Park S.H., Jayawardena J., Kavita U., Shannon M., Bendelac A. CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells. J Immunol 1998, 160:3121-3127.
38. Baumgarth N. A two-phase model of B-cell activation. Immunological Reviews 2000, 176:171-180.
39. Wither J.E., Paterson A.D., Vukusic B. Genetic dissection of B cell traits in New Zealand black mice. The expanded population of B cells expressing up-regulated costimulatory molecules shows linkage to Nba2. European Journal of Immunology 2000, 30:356-365.
40. Grimaldi C.M., Michael D.J., Diamond B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol 2001, 167:1886-1890.
41. Steward M.W., Hay F.C. Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in N/ZBW F1 hybrid mice. Clinical and Experimental Immunology 1976, 26:363-370.
42. Radic M.Z., Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annual Review of Immunology 1994, 12:487-520.
43. Tillman D.M., Jou N.T., Hill R.J., Marion T.N. Both IgM and IgG anti-DNA antibodies are the products of clonally selective B cell stimulation in (NZB x NZW)F1 mice. The Journal of Experimental Medicine 1992, 176:761-779.
44. Kofler R., Duchosal M.A., Johnson M.E., Aguado M.T., Strohal R., Kromer G., et al. The genetic origin of murine lupus-associated autoantibodies. Immunology Letters 1987, 16:265-271.
45. Zouali M., Madaio M.P., Canoso R.T., Stollar B.D. Restriction fragment length polymorphism analysis of the V kappa locus in human lupus. European Journal of Immunology 1989, 19:1757-1760.
46. Isenberg D.A., Ehrenstein M.R., Longhurst C., Kalsi J.K. The origin, sequence, structure, and consequences of developing anti-DNA antibodies. A human perspective. Arthritis and Rheumatism 1994, 37:169-180.
47. Kofler R., Strohal R., Balderas R.S., Johnson M.E., Noonan D.J., Duchosal M.A., et al. Immunoglobulin kappa light chain variable region gene complex organization and immunoglobulin genes encoding anti-DNA autoantibodies in lupus mice. The Journal of Clinical Investigation 1988, 82:852-860.
48. Radic M.Z., Mascelli M.A., Erikson J., Shan H., Weigert M. Ig H and L chain contributions to autoimmune specificities. J Immunol 1991, 146:176-182.
49. Spatz L., Saenko V., Iliev A., Jones L., Geskin L., Diamond B. Light chain usage in anti-double-stranded DNA B cell subsets: role in cell fate determination. The Journal of Experimental Medicine 1997, 185:1317-1326.
50. Padlan E.A. On the nature of antibody combining sites: unusual structural features that may confer on these sites an enhanced capacity for binding ligands. Proteins 1990, 7:112-124.
51. Kalsi J.K., Martin A.C., Hirabayashi Y., Ehrenstein M., Longhurst C.M., Ravirajan C., et al. Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. Molecular Immunology 1996, 33:471-483.
52. Zhang W., Frank M.B., Reichlin M. Production and characterization of human monoclonal anti-idiotype antibodies to anti-dsDNA antibodies. Lupus 2002, 11:362-369.
53. Jerne N.K. Idiotypic networks and other preconceived ideas. Immunological Reviews 1984, 79:5-24.
54. Paul E., Manheimer-Lory A., Livneh A., Solomon A., Aranow C., Ghossein C., et al. Pathogenic anti-DNA antibodies in SLE: idiotypic families and genetic origins. International Reviews of Immunology 1990, 5:295-313.
55. Mendlovic S., Brocke S., Shoenfeld Y., Ben-Bassat M., Meshorer A., Bakimer R., et al. Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:2260-2264.
56. Zouali M., Eyquem A. Idiotypic/antiidiotypic interactions in systemic lupus erythematosus: demonstration of oscillating levels of anti-DNA autoantibodies and reciprocal antiidiotypic activity in a single patient. Annales d'Immunologie 1983, 134C:377-391.
57. Hahn B.H., Singh R.R., Wong W.K., Tsao B.P., Bulpitt K., Ebling F.M. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis and Rheumatism 2001, 44:432-441.
58. Stoll M.L., Price K.D., Silvin C.J., Jiang F., Gavalchin J. Immunization with peptides derived from the idiotypic region of lupus-associated autoantibodies delays the development of lupus nephritis in the (SWR x NZB)F1 murine model. Journal of Autoimmunity 2007, 29:30-37.
59. Hahn B.H., Anderson M., Le E., La Cava A. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis and Rheumatism 2008, 58:2488-2497.
60. Klinman D.M., Shirai A., Conover J., Steinberg A.D. Cross-reactivity of IgG anti-DNA-secreting B cells in patients with systemic lupus erythematosus. European Journal of Immunology 1994, 24:53-58.
61. Aron A.L., Cuellar M.L., Brey R.L., McKeown S., Espinoza L.R., Shoenfeld Y., Gharavi A.E. Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I. Clinical and Experimental Immunology 1995, 101:78-81.
62. Lafer E.M., Rauch J., Andrzejewski C., Mudd D., Furie B., Furie B., et al. Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids. The Journal of Experimental Medicine 1981, 153:897-909.
63. Carroll P., Stafford D., Schwartz R.S., Stollar B.D. Murine monoclonal anti-DNA autoantibodies bind to endogenous bacteria. J Immunol 1985, 135:1086-1090.
64. Dimitrijevic L.A., Radulovic M.I., Ciric B.P., Petricevic M.M., Inic A.B., Nikolic D.N., et al. Human monoclonal IgM DJ binds to ssDNA and human commensal bacteria. Human Antibodies 1999, 9:37-45.
65. Spellerberg M.B., Chapman C.J., Mockridge C.I., Isenberg D.A., Stevenson F.K. Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene: a possible link between infection and lupus. Human Antibodies and Hybridomas 1995, 6:52-56.
66. Limpanasithikul W., Ray S., Diamond B. Cross-reactive antibodies have both protective and pathogenic potential. J Immunol 1995, 155:967-973.
67. Sharma A., Isenberg D.A., Diamond B. Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin. Journal of Autoimmunity 2001, 16:479-484.
68. Kabat E.A., Nickerson K.G., Liao J., Grossbard L., Osserman E.F., Glickman E., et al. A human monoclonal macroglobulin with specificity for alpha(2---8)-linked poly-N-acetyl neuraminic acid, the capsular polysaccharide of group B meningococci and Escherichia coli K1, which crossreacts with polynucleotides and with denatured DNA. The Journal of Experimental Medicine 1986, 164:642-654.
69. Sabbaga J., Line S.R., Potocnjak P., Madaio M.P. A murine nephritogenic monoclonal anti-DNA autoantibody binds directly to mouse laminin, the major non-collagenous protein component of the glomerular basement membrane. European Journal of Immunology 1989, 19:137-143.
70. Tron F., Jacob L., Bach J.F. Binding of a murine monoclonal anti-DNA antibody to Raji cells. Implications for the interpretation of the Raji cell assay for immune complexes. European Journal of Immunology 1984, 14:283-286.
71. Raz E., Ben-Bassat H., Davidi T., Shlomai Z., Eilat D. Cross-reactions of anti-DNA autoantibodies with cell surface proteins. European Journal of Immunology 1993, 23:383-390.
72. Jacob L., Tron F., Bach J.F., Louvard D. A monoclonal anti-DNA antibody also binds to cell-surface protein(s). Proceedings of the National Academy of Sciences of the United States of America 1984, 81:3843-3845.
73. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Medicine 2001, 7:1189-1193.
74. Putterman C., Ulmansky R., Rasooly L., Tadmor B., Ben-Bassat H., Naparstek Y. Down-regulation of surface antigens recognized by systemic lupus erythematosus antibodies on embryonal cells following differentiation and exposure to corticosteroids. European Journal of Immunology 1998, 28:1656-1662.
75. Kowal C., Degiorgio L.A., Lee J.Y., Edgar M.A., Huerta P.T., Volpe B.T., et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:19854-19859.
76. Mostoslavsky G., Fischel R., Yachimovich N., Yarkoni Y., Rosenmann E., Monestier M., et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. European Journal of Immunology 2001, 31:1221-1227.
77. Andre-Schwartz J., Datta S.K., Shoenfeld Y., Isenberg D.A., Stollar B.D., Schwartz R.S. Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clinical Immunology and Immunopathology 1984, 31:261-271.
78. Tsuzaka K., Leu A.K., Frank M.B., Movafagh B.F., Koscec M., Winkler T.H., et al. Lupus autoantibodies to double-stranded DNA cross-react with ribosomal protein S1. J Immunol 1996, 156:1668-1675.
79. Singh S., Chatterjee S., Sohoni R., Badakere S., Sharma S. Sera from lupus patients inhibit growth of P. falciparum in culture. Autoimmunity 2001, 33:253-263.
80. Sun K.H., Hong C.C., Tang S.J., Sun G.H., Liu W.T., Han S.H., et al. Anti-dsDNA autoantibody cross-reacts with the C-terminal hydrophobic cluster region containing phenylalanines in the acidic ribosomal phosphoprotein P1 to exert a cytostatic effect on the cells. Biochemical and Biophysical Research Communications 1999, 263:334-339.
81. Koren E., Koscec M., Wolfson-Reichlin M., Ebling F.M., Tsao B., Hahn B.H., et al. Murine and human antibodies to native DNA that cross-react with the A and D SnRNP polypeptides cause direct injury of cultured kidney cells. J Immunol 1995, 154:4857-4864.
82. Reichlin M., Martin A., Taylor-Albert E., Tsuzaka K., Zhang W., Reichlin M.W., et al. Lupus autoantibodies to native DNA cross-react with the A and D SnRNP polypeptides. The Journal of Clinical Investigation 1994, 93:443-449.
83. Pisetsky D.S. Autoantibodies and their significance. Current Opinion in Rheumatology 1993, 5:549-556.
84. Arinuma Y., Yanagida T., Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis and Rheumatism 2008, 58:1130-1135.
85. Fragoso-Loyo H., Cabiedes J., Orozco-Narvaez A., Davila-Maldonado L., Atisha-Fregoso Y., Diamond B., et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PloS One 2008, 3:e3347.
86. Gilkeson G.S., Bernstein K., Pippen A.M., Clarke S.H., Marion T., Pisetsky D.S., et al. The influence of variable-region somatic mutations on the specificity and pathogenicity of murine monoclonal anti-DNA antibodies. Clinical Immunology and Immunopathology 1995, 76:59-67.
87. Vlahakos D.V., Foster M.H., Adams S., Katz M., Ucci A.A., Barrett K.J., et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney International 1992, 41:1690-1700.
88. Tsao B.P., Ohnishi K., Cheroutre H., Mitchell B., Teitell M., Mixter P., et al. Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. J Immunol 1992, 149:350-358.
89. Ebling F., Hahn B.H. Restricted subpopulations of DNA antibodies in kidneys of mice with systemic lupus. Comparison of antibodies in serum and renal eluates. Arthritis and Rheumatism 1980, 23:392-403.
90. Gilkeson G.S., Pippen A.M., Pisetsky D.S. Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. The Journal of Clinical Investigation 1995, 95:1398-1402.
91. Foster M.H., Cizman B., Madaio M.P. Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins. Laboratory Investigation; a Journal of Technical Methods and Pathology 1993, 69:494-507.
92. Sabbaga J., Pankewycz O.G., Lufft V., Schwartz R.S., Madaio M.P. Cross-reactivity distinguishes serum and nephritogenic anti-DNA antibodies in human lupus from their natural counterparts in normal serum. Journal of Autoimmunity 1990, 3:215-235.
93. Madaio M.P., Carlson J., Cataldo J., Ucci A., Migliorini P., Pankewycz O. Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J Immunol 1987, 138:2883-2889.
94. Putterman C., Limpanasithikul W., Edelman M., Diamond B. The double edged sword of the immune response: mutational analysis of a murine anti-pneumococcal, anti-DNA antibody. The Journal of Clinical Investigation 1996, 97:2251-2259.
95. Faaber P., Rijke T.P., van de Putte L.B., Capel P.J., Berden J.H. Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes. The Journal of Clinical Investigation 1986, 77:1824-1830.
96. Deocharan B., Qing X., Lichauco J., Putterman C. Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 2002, 168:3072-3078.
97. Barnes J.L., Radnik R.A., Gilchrist E.P., Venkatachalam M.A. Size and charge selective permeability defects induced in glomerular basement membrane by a polycation. Kidney International 1984, 25:11-19.
98. Vlahakos D., Foster M.H., Ucci A.A., Barrett K.J., Datta S.K., Madaio M.P. Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J Am Soc Nephrol 1992, 2:1345-1354.
99. Lefkowith J.B., Kiehl M., Rubenstein J., DiValerio R., Bernstein K., Kahl L., et al. Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus. The Journal of Clinical Investigation 1996, 98:1373-1380.
100. Coritsidis G.N., Beers P.C., Rumore P.M. Glomerular uptake of nucleosomes: evidence for receptor-mediated mesangial cell binding. Kidney International 1995, 47:1258-1265.
101. Gay S., Losman M.J., Koopman W.J., Miller E.J. Interaction of DNA with connective tissue matrix proteins reveals preferential binding to type V collagen. J Immunol 1985, 135:1097-1100.
102. Lake R.A., Morgan A., Henderson B., Staines N.A. A key role for fibronectin in the sequential binding of native dsDNA and monoclonal anti-DNA antibodies to components of the extracellular matrix: its possible significance in glomerulonephritis. Immunology 1985, 54:389-395.
103. Termaat R.M., Brinkman K., van Gompel F., van den Heuvel L.P., Veerkamp J.H., Smeenk R.J., et al. Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound DNA/histone complexes. Journal of Autoimmunity 1990, 3:531-545.
104. Pascual V., Farkas L., Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Current Opinion in Immunology 2006, 18:676-682.
105. Lovgren T., Eloranta M.L., Bave U., Alm G.V., Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis and Rheumatism 2004, 50:1861-1872.
106. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science (New York, N.Y 1999, 284:1835-1837.
107. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:2610-2615.
108. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. The Journal of Experimental Medicine 2003, 197:711-723.
109. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annual Review of Immunology 2005, 23:307-336.
110. Doreau A., Belot A., Bastid J., Riche B., Trescol-Biemont M.C., Ranchin B., et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nature Immunology 2009, 10:778-785.
111. Madaio M.P., Hodder S., Schwartz R.S., Stollar B.D. Responsiveness of autoimmune and normal mice to nucleic acid antigens. J Immunol 1984, 132:872-876.
112. Gilkeson G.S., Grudier J.P., Karounos D.G., Pisetsky D.S. Induction of anti-double stranded DNA antibodies in normal mice by immunization with bacterial DNA. J Immunol 1989, 142:1482-1486.
113. Desai D.D., Krishnan M.R., Swindle J.T., Marion T.N. Antigen-specific induction of antibodies against native mammalian DNA in nonautoimmune mice. J Immunol 1993, 151:1614-1626.
114. Bredholt G., Olaussen E., Moens U., Rekvig O.P. Linked production of antibodies to mammalian DNA and to human polyomavirus large T antigen: footprints of a common molecular and cellular process?. Arthritis and Rheumatism 1999, 42:2583-2592.
115. Ehrenstein M.R., Cook H.T., Neuberger M.S. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. The Journal of Experimental Medicine 2000, 191:1253-1258.
116. Kouki P., Marsh J.E., Sacks S.H., Sheerin N.S. Autoimmune renal injury in C3- and C4-deficient mice: a histological and functional study. Nephron 2004, 96:e14-22.
117. Mitchell D.A., Pickering M.C., Warren J., Fossati-Jimack L., Cortes-Hernandez J., Cook H.T., et al. C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol 2002, 168:2538-2543.
118. Napirei M., Karsunky H., Zevnik B., Stephan H., Mannherz H.G., Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nature Genetics 2000, 25:177-181.
119. O'Driscoll m TRX1 DNA exonuclease deficiency, accumulation of single stranded DNA and complex human gnetic disorders. DNA Repair (Amst) 2008, 7:997-1003.
120. el-Roiey A., Sela O., Isenberg D.A., Feldman R., Colaco B.C., Kennedy R.C., et al. The sera of patients with Klebsiella infections contain a common anti-DNA idiotype (16/6) Id and anti-polynucleotide activity. Clinical and Experimental Immunology 1987, 67:507-515.
121. Unni K.K., Holley K.E., McDuffie F.C., Titus J.L. Comparative study of NZB mice under germfree and conventional conditions. The Journal of Rheumatology 1975, 2:36-44.
122. Ray S.K., Putterman C., Diamond B. Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:2019-2024.
123. Wellmann U., Letz M., Herrmann M., Angermuller S., Kalden J.R., Winkler T.H. The evolution of human anti-double-stranded DNA autoantibodies. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:9258-9263.
124. Reeves W.H., Satoh M., Wang J., Chou C.H., Ajmani A.K. Systemic lupus erythematosus. Antibodies to DNA, DNA-binding proteins, and histones. Rheumatic Diseases Clinics of North America 1994, 20:1-28.
125. Fatenejad S., Mamula M.J., Craft J. Role of intermoleuclar/intrastructural B- and T-cell determinants in the diversification of autoantibodies to ribonu-cleoprotein particles. Proceedings of the National Academy of Sciences of the United States of America 1994, 90:12010-12040.
126. James J.A., Gross T., Scofield R.H., Harley J.B. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. The Journal of Experimental Medicine 1995, 181:453-461.
127. Ando D.G., Sercarz E.E., Hahn B.H. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model. J Immunol 1987, 138:3185-3190.
128. Sekigawa I., Ishida Y., Hirose S., Sato H., Shirai T. Cellular basis of in vitro anti-DNA antibody production: evidence for T cell dependence of IgG-class anti-DNA antibody synthesis in the (NZB X NZW)F1 hybrid. J Immunol 1986, 136:1247-1252.
129. Finck B.K., Linsley P.S., Wofsy D. Treatment of murine lupus with CTLA4Ig. Science (New York, N.Y 1994, 265:1225-1227.
130. Mohan C., Shi Y., Laman J.D., Datta S.K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995, 154:1470-1480.
131. Ng T.T., Collins I.E., Kanner S.B., Humphries M.J., Amft N., Wickremasinghe R.G., et al. Integrin signalling defects in T-lymphocytes in systemic lupus erythematosus. Lupus 1999, 8:39-51.
132. Tada Y., Nagasawa K., Yamauchi Y., Tsukamoto H., Niho Y. A defect in the protein kinase C system in T cells from patients with systemic lupus erythematosus. Clinical Immunology and Immunopathology 1991, 60:220-231.
133. Crispin J.C., Tsokos G.C. Novel molecular targets in the treatment of systemic lupus erythematosus. Autoimmunity reviews 2008, 7:256-261.
134. Kyttaris V.C., Wang Y., Juang Y.T., Weinstein A., Tsokos G.C. Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J Immunol 2007, 178:1960-1966.
135. Juang Y.T., Wang Y., Jiang G., Peng H.B., Ergin S., Finnell M., et al. PP2A dephosphorylates Elf-1 and determines the expression of CD3zeta and FcRgamma in human systemic lupus erythematosus T cells. J Immunol 2008, 181:3658-3664.
136. Takeno M., Nagafuchi H., Kaneko S., Wakisaka S., Oneda K., Takeba Y., et al. Autoreactive T cell clones from patients with systemic lupus erythematosus support polyclonal autoantibody production. J Immunol 1997, 158:3529-3538.
137. Khalil M., Inaba K., Steinman R., Ravetch J., Diamond B. T cell studies in a peptide-induced model of systemic lupus erythematosus. J Immunol 2001, 166:1667-1674.
138. Davidson H.W., West M.A., Watts C. Endocytosis, intracellular trafficking, and processing of membrane IgG and monovalent antigen/membrane IgG complexes in B lymphocytes. J Immunol 1990, 144:4101-4109.
139. Hahn B.H., Ebling F.M. Suppression of NZB/NZW murine nephritis by administration of a syngeneic monoclonal antibody to DNA. Possible role of anti-idiotypic antibodies. The Journal of Clinical Investigation 1983, 71:1728-1736.
140. Lan R.Y., Ansari A.A., Lian Z.X., Gershwin M.E. Regulatory T cells: development, function and role in autoimmunity. Autoimmunity Reviews 2005, 4:351-363.
141. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nature Immunology 2007, 8:191-197.
142. Iikuni N., Lourenco E.V., Hahn B.H., La Cava A. Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol 2009, 183:1518-1522.
143. Cuda C.M., Wan S., Sobel E.S., Croker B.P., Morel L. Murine lupus susceptibility locus Sle1a controls regulatory T cell number and function through multiple mechanisms. J Immunol 2007, 179:7439-7447.
144. Hsu W.T., Suen J.L., Chiang B.L. The role of CD4CD25 T cells in autoantibody production in murine lupus. Clinical and Experimental Immunology 2006, 145:513-519.
145. Scalapino K.J., Tang Q., Bluestone J.A., Bonyhadi M.L., Daikh D.I. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol 2006, 177:1451-1459.
146. Monk C.R., Spachidou M., Rovis F., Leung E., Botto M., Lechler R.I., et al. MRL/Mp CD4+, CD25- T cells show reduced sensitivity to suppression by CD4+, CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthritis and Rheumatism 2005, 52:1180-1184.
147. Lee H.Y., Hong Y.K., Yun H.J., Kim Y.M., Kim J.R., Yoo W.H. Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus. Rheumatology (Oxford, England) 2008, 47:789-794.
148. Azab N.A., Bassyouni I.H., Emad Y., Abd El-Wahab G.A., Hamdy G., Mashahit M.A. CD4+CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clinical Immunology (Orlando, Fla 2008, 127:151-157.
149. Yan B., Ye S., Chen G., Kuang M., Shen N., Chen S. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis and Rheumatism 2008, 58:801-812.
150. Erikson J., Radic M.Z., Camper S.A., Hardy R.R., Carmack C., Weigert M. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 1991, 349:331-334.
151. Offen D., Spatz L., Escowitz H., Factor S., Diamond B. Induction of tolerance to an IgG autoantibody. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:8332-8336.
152. Fulcher D.A., Basten A. Whither the anergic B-cell?. Autoimmunity 1994, 19:135-140.
153. Venkatesh J., Peeva E., Xu X., Diamond B. Cutting Edge: Hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells. J Immunol 2006, 176:3311-3314.
154. Mackay M., Stanevsky A., Wang T., Aranow C., Li M., Koenig S., et al. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. The Journal of Experimental Medicine 2006, 203:2157-2164.
155. McGaha T.L., Karlsson M.C., Ravetch J.V. FcgammaRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. J Immunol 2008, 180:5670-5679.
156. Jacobi A.M., Zhang J., Mackay M., Aranow C., Diamond B. Phenotypic characterization of autoreactive B cells-checkpoints of B cell tolerance in patients with systemic lupus erythematosus. PloS one 2009, 4:e5776.
157. Chen C., Nagy Z., Prak E.L., Weigert M. Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing. Immunity 1995, 3:747-755.
158. Suzuki N., Mihara S., Sakane T. Development of pathogenic anti-DNA antibodies in patients with systemic lupus erythematosus. Faseb J 1997, 11:1033-1038.
159. Roark J.H., Kuntz C.L., Nguyen K.A., Caton A.J., Erikson J. Breakdown of B cell tolerance in a mouse model of systemic lupus erythematosus. The Journal of Experimental Medicine 1995, 181:1157-1167.
160. Strasser A., Whittingham S., Vaux D.L., Bath M.L., Adams J.M., Cory S., et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:8661-8665.
161. Kuo P., Bynoe M.S., Wang C., Diamond B. Bcl-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset. European Journal of Immunology 1999, 29:3168-3178.
162. Bynoe M.S., Grimaldi C.M., Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:2703-2708.
163. Peeva E., Grimaldi C., Spatz L., Diamond B. Bromocriptine restores tolerance in estrogen-treated mice. The Journal of Clinical Investigation 2000, 106:1373-1379.
164. Westhoff C.M., Whittier A., Kathol S., McHugh J., Zajicek C., Shultz L.D., et al. DNA-binding antibodies from viable motheaten mutant mice: implications for B cell tolerance. J Immunol 1997, 159:3024-3033.
165. Cyster J.G., Goodnow C.C. Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. Immunity 1997, 6:509-517.
166. Nitschke L., Carsetti R., Ocker B., Kohler G., Lamers M.C. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol 1997, 7:133-143.
167. Chan V.W., Meng F., Soriano P., DeFranco A.L., Lowell C.A. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 1997, 7:69-81.
168. Justement L.B., Campbell K.S., Chien N.C., Cambier J.C. Regulation of B cell antigen receptor signal transduction and phosphorylation by CD45. Science 1991, 252:1839-1842.
169. Cyster J.G., Healy J.I., Kishihara K., Mak T.W., Thomas M.L., Goodnow C.C. Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45. Nature 1996, 381:325-328.
170. Sato S., Hasegawa M., Fujimoto M., Tedder T.F., Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635-6643.
171. Ma J., Xu J., Madaio M.P., Peng Q., Zhang J., Grewal I.S., et al. Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. J Immunol 1996, 157:417-426.
172. Desai-Mehta A., Lu L., Ramsey-Goldman R., Datta S.K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. The Journal of Clinical Investigation 1996, 97:2063-2073.
173. Linterman M.A., Rigby R.J., Wong R.K., Yu D., Brink R., Cannons J.L., et al. Follicular helper T cells are required for systemic autoimmunity. The Journal of experimental medicine 2009, 206:561-576.
174. Boackle S.A., Holers V.M., Chen X., Szakonyi G., Karp D.R., Wakeland E.K., et al. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 2001, 15:775-785.
175. Takahashi K., Kozono Y., Waldschmidt T.J., Berthiaume D., Quigg R.J., Baron A., et al. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol 1997, 159:1557-1569.
176. Chen Z., Koralov S.B., Kelsoe G. Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. The Journal of Experimental Medicine 2000, 192:1339-1352.
177. Texido G., Su I.H., Mecklenbrauker I., Saijo K., Malek S.N., Desiderio S., et al. The B-cell-specific Src-family kinase Blk is dispensable for B-cell development and activation. Molecular and Cellular Biology 2000, 20:1227-1233.
178. Hom G., Graham R.R., Modrek B., Taylor K.E., Ortmann W., Garnier S., et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. The New England Journal of Medicine 2008, 358:900-909.
179. Lee Y.H., Rho Y.H., Choi S.J., Ji J.D., Song G.G., Nath S.K., et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases-a meta-analysis. Rheumatology (Oxford, England) 2007, 46:49-56.
180. Kozyrev S.V., Abelson A.K., Wojcik J., Zaghlool A., Linga Reddy M.V., Sanchez E., et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nature genetics 2008, 40:211-216.
181. Xu Y., Harder K.W., Huntington N.D., Hibbs M.L., Tarlinton D.M. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 2005, 22:9-18.
182. Liossis S.N., Solomou E.E., Dimopoulos M.A., Panayiotidis P., Mavrikakis M.M., Sfikakis P.P. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Investig Med 2001, 49:157-165.
183. Stuber E., Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. The Journal of Experimental Medicine 1996, 183:979-989.
184. Prokunina L., Castillejo-Lopez C., Oberg F., Gunnarsson I., Berg L., Magnusson V., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nature Genetics 2002, 32:666-669.
185. Chen J.Y., Wang C.M., Ma C.C., Luo S.F., Edberg J.C., Kimberly R.P., et al. Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients. Arthritis and Rheumatism 2006, 54:3908-3917.
186. Su K., Yang H., Li X., Li X., Gibson A.W., Cafardi J.M., et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol 2007, 178:3272-3280.
187. Kelly J.A., Kelley J.M., Kaufman K.M., Kilpatrick J., Bruner G.R., Merrill J.T., et al. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes and Immunity 2008, 9:187-194.
188. Smeenk R.J., van den Brink H.G., Brinkman K., Termaat R.M., Berden J.H., Swaak A.J. Anti-dsDNA: choice of assay in relation to clinical value. Rheumatology International 1991, 11:101-107.
189. Takeuchi Y., Ishikawa O., Miyachi Y. The comparative study of anti-double stranded DNA antibody levels measured by radioimmunoassay and enzyme-linked immunosorbent assay in systemic lupus erythematosus. The Journal of Dermatology 1997, 24:297-300.
190. Kalled S.L., Cutler A.H., Datta S.K., Thomas D.W. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998, 160:2158-2165.
191. Mihara M., Tan I., Chuzhin Y., Reddy B., Budhai L., Holzer A., et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. The Journal of Clinical Investigation 2000, 106:91-101.
192. Daikh D.I., Finck B.K., Linsley P.S., Hollenbaugh D., Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997, 159:3104-3108.
193. Merrill J.T., Shanahan J.C., Latinis K.M., Oates J.C., Utset T.O., Gordon C., et al. Efficacy and safety of Rituximab in patients with moderately to severely active SLE: Results from the randomized, double-blind phase II/III study EXPLORER. Arthritis and Rheumatism 2008, LB12.
194. Li Y., Chen F., Putt M., Koo Y.K., Madaio M., Cambier J.C., et al. B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J Immunol 2008, 181:2961-2972.
195. Furie R., Looney R.J., Rovin J.M., Latinish G., Appel J., Sanchez-Guerrero F.C., et al. Efficacy and safety of Rituximab in subjects with active proliferative Lupous Nephritis (LN): Results from the randomized, Double-Blind Phase III LUNAR study. Arthritis and Rheumatism 2009, S1149.
196. Ramanujam M., Wang X., Huang W., Liu Z., Schiffer L., Tao H., et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. The Journal of Clinical Investigation 2006, 116:724-734.
197. Jacob C.O., Pricop L., Putterman C., Koss M.N., Liu Y., Kollaros M., et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol 2006, 177:2671-2680.
198. Wallace D.J., Stohl W., Furie R.A., Lisse J.R., McKay J.D., Merrill J.T., et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis and Rheumatism 2009, 61:1168-1178.
199. Navarra S., Guzman R., Gallacher A., Levy R.A., Li E.K., Thomas M., et al. Belimumab, a BLyS-Specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: Efficacy and safety results from the Phase 3 BLISS-52 study. Arthritis and Rheumatism 60 2009, 3859.